Showing 1 - 10 of 73
We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...
Persistent link: https://www.econbiz.de/10014372489
This paper presents an endogenous growth model that explains the evolution of the first and second moments of productivity growth at the aggregate and firm level during the post-war period. Growth is driven by the development of both (i) idiosyncratic R&D innovations and (ii) general innovations...
Persistent link: https://www.econbiz.de/10012467175
Employing a sample of renowned U.S. inventors that combines biographical detail with information on the patents they received over their careers, we highlight the impact of early U.S. patent institutions in providing broad access to economic opportunity and in encouraging trade in new...
Persistent link: https://www.econbiz.de/10012467721
cancer was declared in 1971. We assess the contribution of pharmaceutical innovation to the increase in cancer survival rates …
Persistent link: https://www.econbiz.de/10012468366
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation …
Persistent link: https://www.econbiz.de/10012468658
This study analyzes the effect of pharmaceutical price regulation on delays in new drug launches. Because low price in one market may 'spill-over' to others, though parallel trade and external referencing, manufacturers may rationally prefer longer delay or non-launch to accepting a low price....
Persistent link: https://www.econbiz.de/10012468823
We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Our data cover virtually all of the diseases borne by people in 52 countries during the period 1982-2001, and enable us to...
Persistent link: https://www.econbiz.de/10012468944
During the last several years, government spending on drugs used to treat schizophrenia and other psychotic illnesses has increased at more than 30% per year, with the $3 billion in 2001 Medicaid expenditures exceeding spending in any other therapeutic category. This growth has been primarily...
Persistent link: https://www.econbiz.de/10012469072
This paper investigates changes in the output and productivity of research and development activities in Japanese manufacturing firms over the 1980s and 1990s. Evidence from aggregate patent and R&D statistics and a micro-level analysis of R&D productivity at the firm-level suggest that there...
Persistent link: https://www.econbiz.de/10012469265
This paper argues that the late 1990s boom in ICT investment was unsustainable for both macro and micro reasons; we are unlikely again to witness an interval in which computer hardware investment grows at an annual rate greater than 30 percent for five straight years. Analysts who base their...
Persistent link: https://www.econbiz.de/10012469266